FDA red and green lights: August 2025
Boehringer’s Hernexeos beats Bayer’s sevabertinib to the US.
World Lung 2025 – Summit's Harmoni guessing game
Investors now have more reasons to doubt Harmoni's ability to back US approval.
MacroGenics faces new competition
Duality takes its Adam9-targeting conjugate into the clinic.
Colorectal cancer is next for VEGF bispecifics
Pumitamig is the latest to be tested in first-line disease.
The month ahead: September’s upcoming events
It’s a new term for biotech and its investors.
